Successful ABO-incompatible kidney transplantation with antibody removal and standard immunosuppression

Abstract

ABO-incompatible (ABOi) kidney transplantation is an established therapy, though its implementation to date has been in part limited by the requirement for additional immunosuppression. Here, we describe the outcomes of 37 patients undergoing ABOi kidney transplantation utilizing perioperative antibody depletion and receiving an identical tacrolimus-based immunosuppressive regimen to contemporaneous ABO-compatible (ABOc) recipients, with the exception that mycophenolate was commenced earlier (7-14 days pretransplant). Antibody depletion was scheduled according to baseline anti-ABO antibody titer (tube IAT method: median 1:128, range 1:8 to 1:4096). Patient and graft survival for the 37 ABOi recipients was 100% after a median 26 months (interquartile range [IQR] 18-32). Eight rejection episodes (two antibody-mediated and six cellular) in ABOi recipients were successfully treated with biopsy-proven resolution. Latest median eGFR is 50 mL/min × 1.73 m2 (IQR 40-64) for ABOi patients and 54 mL/min × 1.73 m2 (IQR 44-66) in the ABOc patients (p = 0.25). We conclude that ABOi transplantation can be performed successfully with perioperative antibody removal and conventional immunosuppression. This suggests that access to ABOi transplantation can include a broader range of end-stage kidney disease patients. This study describes excellent outcomes for patients undergoing ABO-incompatible kidney transplantation with perioperative antibody depletion and otherwise conventional immunosuppression, reinforcing that ABO-incompatible transplantation may be an option for a broad range of end-stage kidney disease patients. © 2011 The American Society of Transplantation and the American Society of Transplant Surgeons.